Skip to main content

Advertisement

SpringerLink
Log in

Clinicopathological predictors of postoperative long-term myasthenic status in resected thymoma with myasthenia gravis

  • Original Article
  • Published:
Surgery Today Aims and scope Submit manuscript

Abstract

Purpose

Surgical patients with thymoma and myasthenia gravis (MG) must have their MG status and oncological outcomes critically monitored. We aimed to identify clinicopathological predictors of the postoperative MG status.

Methods

We conducted a retrospective review of 40 consecutive surgical patients with MG-related thymomas between 2002 and 2020. The quantitative myasthenia gravis score (QMGS) and Myasthenia Gravis Foundation of America post-intervention status (MGFA-PIS) were used to evaluate postoperative MG status.

Results

All patients underwent extended total thymectomy. The most common WHO type was type B2 (32%), while 65% of patients had type B1–B3 and 35% had type A–AB thymomas. Eleven patients (28%) achieved controlled MG status in MGFA-PIS 6 months after surgery. This controlled status was observed more frequently in type A–AB than in B1–B3 (57% vs. 12%, p = 0.007). In a multivariate analysis, WHO type (A–AB or B1–B3) was an independent predictor of worsening episodes of MG based on the QMGS (Type B1–B3, hazard ratio: 3.23, 95% confidence interval: 1.12–9.25). At the last follow-up, 23 patients (58%) achieved controlled MG status. The 5-year overall survival rate of all patients was 93.7%.

Conclusion

The WHO type of thymoma is an informative predictor of postoperative MG status in patients with MG-related thymoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Chan JKC, Lanyuejoul S, Marx A (eds). Tumours of the thymus in WHO classification of tumours editorial board. In: Thoracic tumours. 5th ed. International Agency for Research on Cancer; 2021; pp. 319–44.

  2. Marx A, Willcox N, Leite MI, Chuang WY, Schalke B, Nix W, et al. Thymoma and paraneoplastic myasthenia gravis. Autoimmunity. 2010;43:413–27.

    Article  CAS  PubMed  Google Scholar 

  3. Wang F, Pang L, Fu J, Shen Y, Wei Y, Tan L, et al. Postoperative survival for patients with thymoma complicating myasthenia gravis-preliminary retrospective results of the ChART database. J Thorac Dis. 2016;8:711–7.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Nakajima J, Okumura M, Yano M, Date H, Onuki T, Haniuda M, et al. Myasthenia gravis with thymic epithelial tumour: a retrospective analysis of a Japanese database. Eur J Cardiothorac Surg. 2016;49:1510–5.

    Article  PubMed  Google Scholar 

  5. Ruffini E, Detterbeck F, Van Raemdonck D, Rocco G, Thomas P, Weder W, et al. Tumours of the thymus: a cohort study of prognostic factors from the European Society of Thoracic Surgeons database. Eur J Cardiothorac Surg. 2014;46:361–8.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Menon D, Katzberg H, Barnett C, Pal P, Bezjak A, Keshavjee S, et al. Thymoma pathology and myasthenia gravis outcomes. Muscle Nerve. 2021;63:868–73.

    Article  PubMed  Google Scholar 

  7. Weis CA, Yao X, Deng Y, Detterbeck FC, Marino M, Nicholson AG, et al. The impact of Thymoma Histotype on prognosis in a worldwide database. J Thorac Oncol. 2015;10:367–72.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96:114–22.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, et al. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med. 2016;375:511–22.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Asamura H. Lung, pleural, and thymic tumours. In: Brierley J, Gospodarowicz MK, Wittekind C, editors. TNM classification of malignant tumours. 8th ed. UK: Wiley; 2017. p. 105–17.

    Google Scholar 

  11. Detterbeck FC, Stratton K, Giroux D, Asamura H, Crowley J, Falkson C, et al. The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol. 2014;9:S65-72.

    Article  PubMed  Google Scholar 

  12. Keesey J. A treatment algorithm for autoimmune myasthenia in adults. Ann N Y Acad Sci. 1998;841:753–68.

    Article  ADS  CAS  PubMed  Google Scholar 

  13. Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, Harms L, et al. European Federation of Neurological Societies. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010;17(7):893–902.

    Article  CAS  PubMed  Google Scholar 

  14. Chaurasia A, Harel O. Using AIC in multiple linear regression framework with multiply imputed data. Health Serv Outcomes Res Methodol. 2012;12(2–3):219–33.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Masaoka A, Yamakawa Y, Niwa H, Fukai I, Kondo S, Kobayashi M, et al. Extended thymectomy for myasthenia gravis patients: a 20-year review. Ann Thorac Surg. 1996;62:853–9.

    Article  CAS  PubMed  Google Scholar 

  16. López-Cano M, Ponseti-Bosch JM, Espin-Basany E, Sánchez-García JL, Armengol-Carrasco M. Clinical and pathologic predictors of outcome in thymoma-associated myasthenia gravis. Ann Thorac Surg. 2003;76:1643–9.

    Article  PubMed  Google Scholar 

  17. Tian W, Li X, Tong H, Weng W, Yang F, Jiang G, et al. Surgical effect and prognostic factors of myasthenia gravis with thymomas. Thorac Cancer. 2020;11:1288–96.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Okumura M, Miyoshi S, Fujii Y, Takeuchi Y, Shiono H, Inoue M, et al. Clinical and functional significance of WHO classification on human thymic epithelial neoplasms. A study of 146 consecutive tumors. Am J Surg Pathol. 2001;25:103–10.

    Article  CAS  PubMed  Google Scholar 

  19. Suzuki S, Utsugisawa K, Suzuki N. Overlooked non-motor symptoms in myasthenia gravis. J Neurol Neurosurg Psychiatry. 2013;84:989–94.

    Article  PubMed  Google Scholar 

  20. Ströbel P, Helmreich M, Menioudakis G, Lewin SR, Rüdiger T, Bauer A, et al. Paraneoplastic myasthenia gravis correlates with generation of mature naive CD4 (+) T cells in thymomas. Blood. 2002;100:159–66.

    Article  PubMed  Google Scholar 

  21. Yamada Y, Weis CA, Thelen J, Sticht C, Schalke B, Ströbel P, et al. Thymoma Associated Myasthenia Gravis (TAMG): differential expression of functional pathways in relation to MG status in different thymoma histotypes. Front Immunol. 2020;11:664.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Leuzzi G, Meacci E, Cusumano G, Cesario A, Chiappetta M, Dall’armi V, et al. Thymectomy in myasthenia gravis: proposal for a predictive score of postoperative myasthenic crisis. Eur J Cardiothorac Surg. 2014;45:e76-88.

    Article  PubMed  Google Scholar 

  23. Yu S, Lin J, Fu X, Li J, Li Y, Chen B, et al. Risk factors of myasthenic crisis after thymectomy in 178 generalized myasthenia gravis patients in a five-year follow-up study. Int J Neurosci. 2014;124:792–8.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors acknowledge Prof. Yasunori Sato, Department of Preventive Medicine and Public Health, Keio University School of Medicine, for conducting a statistical review.

Funding

This study was partially supported by institutional grants from Covidien Japan, Johnson and Johnson Medical Company, Taiho Pharmaceutical Company, Eli Lilly Japan, Astellas Pharma, AstraZeneca, Shionogi, Chugai Pharmaceutical, Daiichi-Sankyo Company, and Kyowa Kirin.

Author information

Authors and Affiliations

  1. Division of Thoracic Surgery, Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan

    Takahiro Suzuki, Tomoyuki Hishida, Yu Okubo, Kyohei Masai, Kaoru Kaseda, Keisuke Asakura & Hisao Asamura

  2. Department of Neurology, Keio University School of Medicine, Tokyo, Japan

    Shigeaki Suzuki

  3. Division of Diagnostic Pathology, Keio University School of Medicine, Tokyo, Japan

    Katsura Emoto

Authors
  1. Takahiro Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tomoyuki Hishida
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shigeaki Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yu Okubo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kyohei Masai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kaoru Kaseda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Keisuke Asakura
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Katsura Emoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hisao Asamura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tomoyuki Hishida.

Ethics declarations

Conflict of interests

The authors declare no conflict of interest in association with the present study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Suzuki, T., Hishida, T., Suzuki, S. et al. Clinicopathological predictors of postoperative long-term myasthenic status in resected thymoma with myasthenia gravis. Surg Today (2024). https://doi.org/10.1007/s00595-024-02806-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00595-024-02806-0

Keywords

Search

Navigation